Skip Nav Destination
Issues
15 August 2008
-
Cover Image
Cover Image
Human D52 or D53 expression is associated with reduced cell area and actin stress fibers in 3T3 cells. A stably transfected cell line expressing D53 is shown labeled with FITC-phalloidin (green), and DAPI as a nuclear counterstain (blue). Cells with high D53 expression were small, with poor actin stress fibers, whereas cells with undetectable to low D53 expression were larger, with prominent actin stress fibers (original magnification, x400). For further details, please see Shehata and colleagues on page 5050 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Review
Human Cancer Biology
Overexpression of Stromal Cell–Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas
Federica Barbieri; Adriana Bajetto; Ralf Stumm; Alessandra Pattarozzi; Carola Porcile; Gianluigi Zona; Alessandra Dorcaratto; Jean-Louis Ravetti; Francesco Minuto; Renato Spaziante; Gennaro Schettini; Diego Ferone; Tullio Florio
Cancer Therapy: Preclinical
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Roberto Bianco; Roberta Rosa; Vincenzo Damiano; Gennaro Daniele; Teresa Gelardi; Sonia Garofalo; Valeria Tarallo; Sandro De Falco; Davide Melisi; Roberto Benelli; Adriana Albini; Anderson Ryan; Fortunato Ciardiello; Giampaolo Tortora
Imaging, Diagnosis, Prognosis
Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma
Paul L. Crispen; Yuri Sheinin; Timothy J. Roth; Christine M. Lohse; Susan M. Kuntz; Xavier Frigola; R. Houston Thompson; Stephen A. Boorjian; Haidong Dong; Bradley C. Leibovich; Michael L. Blute; Eugene D. Kwon
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Richard W. Tothill; Anna V. Tinker; Joshy George; Robert Brown; Stephen B. Fox; Stephen Lade; Daryl S. Johnson; Melanie K. Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A. Hung; Yoke-Eng Chiew; Izhak Haviv; Australian Ovarian Cancer Study Group; Dorota Gertig; Anna deFazio; David D.L. Bowtell
Gefitinib Induction of In vivo Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3
Antonella Zannetti; Francesca Iommelli; Rosa Fonti; Angela Papaccioli; Jvana Sommella; Anna Lettieri; Giuseppe Pirozzi; Roberto Bianco; Giampaolo Tortora; Marco Salvatore; Silvana Del Vecchio
Nuclear and Cytoplasmic Expression of ERβ1, ERβ2, and ERβ5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients
Abeer M. Shaaban; Andrew R. Green; Suchita Karthik; Yalda Alizadeh; Thomas A. Hughes; Lynn Harkins; Ian O. Ellis; John F. Robertson; Emma C. Paish; Philippa T.K. Saunders; Nigel P. Groome; Valerie Speirs
Cancer Therapy: Clinical
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
Cédric Ménard; François Ghiringhelli; Stephan Roux; Nathalie Chaput; Christine Mateus; Ursula Grohmann; Sophie Caillat-Zucman; Laurence Zitvogel; Caroline Robert
Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non–Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505
Isamu Okamoto; Takashi Nishimura; Masaki Miyazaki; Hiroshige Yoshioka; Akihito Kubo; Koji Takeda; Noriyuki Ebi; Shunichi Sugawara; Nobuyuki Katakami; Masahiro Fukuoka; Kazuhiko Nakagawa
C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients
Scott S. Tykodi; Nobuharu Fujii; Nathalie Vigneron; Sharon M. Lu; Jeffrey K. Mito; Maureen X. Miranda; Jeffrey Chou; Lilien N. Voong; John A. Thompson; Brenda M. Sandmaier; Peter Cresswell; Benoît Van den Eynde; Stanley R. Riddell; Edus H. Warren
Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant
Robert J. Lechleider; Philip M. Arlen; Kwong-Yok Tsang; Seth M. Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L. Dahut; James L. Gulley
Letters to the Editor
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.